Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3377759)

Published in Curr Oncol on June 01, 2012

Authors

A Black1, D Morris

Author Affiliations

1: Department of Oncology, University of Calgary, Calgary, AB.

Associated clinical trials:

Tarceva Italian Lung Optimization tRial (TAILOR) | NCT00637910

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | NCT00932893

A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 | NCT01449461

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer | NCT01121575

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | NCT01526928

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene | NCT00932451

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | NCT01337765

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | NCT01363232

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | NCT01306045

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | NCT01283516

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | NCT01449058

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | NCT01023737

PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer | NCT01000025

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT01395758

ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | NCT01244191

Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | NCT01514864

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | NCT01229150

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | NCT01487265

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | NCT00994123

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | NCT01266057

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | NCT00667082

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | NCT01294306

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer | NCT01362296

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations | NCT00977470

Selumetinib in Cancers With BRAF Mutations | NCT00888134

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION) | NCT01377376

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations | NCT00525148

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) | NCT01147211

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | NCT01155453

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | NCT00711594

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors | NCT01171924

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | NCT00861627

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | NCT01221077

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | NCT00397384

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | NCT01027598

Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors | NCT00692640

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib | NCT00993499

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM) | NCT01203917

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | NCT01451632

-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | NCT01441128

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer (NSCLC) | NCT01542437

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC) | NCT01515969

Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer | NCT00976677

Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | NCT00891579

Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer (HCH003) | NCT01090830

Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer | NCT00907179

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers | NCT00738751

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC) | NCT01027676

Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors | NCT01324258

Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | NCT00798720

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554

Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment (ICARUS) | NCT01530334

Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer (ISCAN) | NCT01404260

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia | NCT01159301

Phase I Study of Pazopanib and Vorinostat | NCT01339871

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer | NCT01500824

BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours | NCT01169675

Articles cited by this

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23

Lung cancer. N Engl J Med (2008) 13.49

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol (2010) 8.56

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol (2003) 8.17

The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45

Regulation, substrates and functions of src. Biochim Biophys Acta (1996) 5.45

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol (2008) 4.86

Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62

Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 4.07

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59

Role of Src expression and activation in human cancer. Oncogene (2000) 3.41

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets (2008) 3.36

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol (2008) 3.03

Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer (2006) 2.52

Bromodomains as therapeutic targets. Expert Rev Mol Med (2011) 2.52

Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res (2002) 2.48

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther (2004) 2.25

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood (2006) 2.24

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res (2001) 1.87

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol (2009) 1.68

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67

Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res (2003) 1.59

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer (2009) 1.32

Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol (1978) 1.32

Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Lett (2009) 1.31

Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer (2010) 1.13

The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. Oncol Rep (2009) 0.91

Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells. Oncol Rep (2007) 0.88

Articles by these authors

(truncated to the top 100)

Using oligonucleotide probe arrays to access genetic diversity. Biotechniques (1995) 12.18

Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat Genet (1996) 5.77

Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med (1996) 5.35

Early discharge after hernia repair. Lancet (1968) 5.29

Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med (1997) 4.27

Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A (2000) 3.47

Language discrimination by human newborns and by cotton-top tamarin monkeys. Science (2000) 2.89

Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol (1985) (1992) 2.85

Discrepant legacies: premature mortality in two industrial towns. Soc Sci Med (1991) 2.62

Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry (2010) 2.59

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant (2002) 2.37

Surgical operation rates: a twelve year experience in Stockton on Tees. Ann R Coll Surg Engl (1983) 2.35

The Motor Activity Log-28: assessing daily use of the hemiparetic arm after stroke. Neurology (2006) 2.29

The declining specificity of exercise radionuclide ventriculography. N Engl J Med (1983) 2.22

Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry (2012) 2.20

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol (2006) 2.13

Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1995) 2.12

Scleroderma and silicone gel breast prostheses--the Sydney study revisited. Aust N Z J Med (1996) 2.04

Admissions from surgical waiting lists. Br J Prev Soc Med (1969) 1.95

Effects of methods of admitting emergencies on use of hospital beds. Br J Prev Soc Med (1971) 1.86

Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol (1997) 1.71

Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry (1997) 1.63

Mycobacterium bovis as an occupational hazard in abattoir workers. Aust N Z J Med (1988) 1.62

Evaluation of diagnosis-related groups in the National Health Service. Community Med (1989) 1.60

Increased viral titer through concentration of viral harvests from retroviral packaging lines. Hum Gene Ther (1993) 1.58

A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet (1995) 1.49

Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol (1990) 1.48

Pathologists' views on consent for autopsy. J R Soc Med (2002) 1.45

Routine hospital admission in twin pregnancy between 26 and 30 weeks' gestation. Lancet (1990) 1.42

Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA (1996) 1.41

MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window. Neurology (2005) 1.40

Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabet Med (2011) 1.26

Surgical waiting lists. Br Med J (Clin Res Ed) (1984) 1.26

Removal of nasogastric tube fragments from three horses. J Am Vet Med Assoc (1992) 1.14

Simulation of emergency bed occupancy. Health Serv Res (1967) 1.13

Migration and differentiation of adult rat subventricular zone progenitor cells transplanted into the adult rat striatum. Neuroscience (2003) 1.11

Extended spectrum beta-lactamase production and fluorquinolone resistance in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis (1998) 1.10

The kinetic properties of human placental choline acetyltransferase. Biochem J (1971) 1.10

Expression of biologically active recombinant keratinocyte growth factor. Structure/function analysis of amino-terminal truncation mutants. J Biol Chem (1993) 1.08

Gastrin: growth enhancing effects on human gastric and colonic tumour cells. Br J Cancer (1989) 1.08

Opiate addiction and plasma beta-endorphin-like immunoreactivity: methadone maintained, recently detoxified and early naltrexone treated ex-addicts. Alcohol Drug Res (1987) 1.07

Performance indicators in health service management--a clinical analogy. Hosp Health Serv Rev (1986) 1.07

Intragastric N-nitrosation is unlikely to be responsible for gastric carcinoma developing after operations for duodenal ulcer. Gut (1984) 1.05

Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res (2001) 1.04

Comparison of two methods of preparing enzyme-antibody conjugates: application of these conjugates for enzyme immunoassay. Anal Biochem (1979) 1.04

Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis. Neuroscience (2009) 1.03

Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci (1999) 1.03

Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res (1999) 1.03

Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant (2002) 1.02

A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis (1985) 1.02

Phylogenetics of social behavior in Australian gall-forming thrips: evidence from mitochondrial DNA sequence, adult morphology and behavior, and gall morphology. Mol Phylogenet Evol (1998) 1.02

ED length-of-stay and illness severity in dizzy and chest-pain patients. Am J Emerg Med (1994) 0.99

Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers. Br J Cancer (2013) 0.99

Quantitative analysis of the tomographic thallium-201 myocardial bullseye display: critical role of correcting for patient motion. J Nucl Med (1988) 0.99

The choline acetyltransferase of human placenta. Biochem J (1966) 0.99

Embolization of pulmonary pseudoaneurysms secondary to metastatic synovial sarcoma of the right atrium. J Vasc Interv Radiol (1999) 0.99

The effect of sulphydryl and other disulphide reducing agents on choline acetyltransferase activity estimated with synthetic acetyl-CoA. J Neurochem (1967) 0.99

Changing use of coronary angioplasty and coronary bypass surgery in the treatment of chronic coronary artery disease. Am J Cardiol (1990) 0.98

National clinical guidelines for management of the palatally ectopic maxillary canine. Br Dent J (2012) 0.98

mdm-2 gene amplification in 3T3-L1 preadipocytes. Differentiation (1999) 0.97

Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther (2008) 0.97

Control of Mycobacterium tuberculosis growth by activated natural killer cells. Clin Exp Immunol (2012) 0.97

Reduced fractional anisotropy in the uncinate fasciculus in patients with major depression carrying the met-allele of the Val66Met brain-derived neurotrophic factor genotype. Am J Med Genet B Neuropsychiatr Genet (2012) 0.97

Association between prenatal exposure to methylmercury and developmental outcomes in Seychellois children: effect modification by social and environmental factors. Neurotoxicology (1999) 0.97

Acrogeria. Proc R Soc Med (1957) 0.96

A randomized trial of photocoagulation or injection sclerotherapy for the treatment of first- and second-degree hemorrhoids. Dis Colon Rectum (1985) 0.96

Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Bone Marrow Transplant (1999) 0.95

Halogen substituted derivatives of acetylcholine as inhibitors of choline acetyltransferase. Life Sci (1969) 0.95

Causes of higher in-hospital mortality in women than in men after acute myocardial infarction. Am J Cardiol (1994) 0.95

MacFee incision: a safe approach to the neck. South Med J (1993) 0.94

Immunoglobulin produced by guinea-pig leukaemic B lymphocytes: its source and use as a monitor of tumour load. Immunology (1980) 0.94

Inhibitory effects of the gastrin receptor antagonist (L-365,260) on gastrointestinal tumor cells. Cancer (1991) 0.94

Genome-wide linkage analysis of 972 bipolar pedigrees using single-nucleotide polymorphisms. Mol Psychiatry (2011) 0.93

Chymotryptic conversion of bacterial membrane ATPase to an active form with modified alpha chains and defective membrane binding properties. Biochemistry (1976) 0.92

Gastrointestinal bleeding in patients on bromocriptine. Lancet (1976) 0.92

Critical research needs for managing coral reef marine protected areas: perspectives of academics and managers. J Environ Manage (2012) 0.92

Isotopic exchange between acetylcholine and [Me-14C] choline catalysed by human placental choline acetyltransferase. Biochem J (1969) 0.90

Electrical treatment of Lewis lung carcinoma in mice. J Surg Res (1986) 0.90

Temperature acclimatization and protein synthesis in the goldfish mucosa. Experientia (1966) 0.89

Methanol poisoning complicated by myoglobinuric renal failure. Am J Emerg Med (1985) 0.89

Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study. Psychopharmacol Bull (1997) 0.89

Antimicrobial resistance and phage types of human and non-human Salmonella enterica isolates in Ireland, 1998-2003. Commun Dis Public Health (2004) 0.89

Parental reactions to perinatal death. Proc R Soc Med (1976) 0.89

Clonal expansion may account for high levels of quinolone resistance in Salmonella enterica serovar enteritidis. Appl Environ Microbiol (2005) 0.88

Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond) (2005) 0.88

Epilepsy and pregnancy--a review of 98 pregnancies. Aust N Z J Obstet Gynaecol (1990) 0.87

Antibiotic resistance amongst Salmonella enterica species isolated in the Republic of Ireland. J Antimicrob Chemother (1998) 0.87

Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype. J Clin Neurosci (2007) 0.87

Commonly used disinfectants fail to eradicate Salmonella enterica biofilms from food contact surface materials. Appl Environ Microbiol (2013) 0.87

High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant (2003) 0.86

PrP genotype progression in flocks participating in the National Scrapie Plan for Great Britain. Vet Rec (2006) 0.86

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol (2009) 0.86

Osteoporosis associated with mastocytosis confined to bone: report of two cases. Bone (1989) 0.86

A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. Curr Oncol (2012) 0.86

Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women with polycystic ovary syndrome. Fertil Steril (2000) 0.85

Disposal arrangements for second trimester fetuses. Br J Obstet Gynaecol (1988) 0.85

A prospective study of proneness to acute respiratory illness in the first two years of life. Int J Epidemiol (1994) 0.85

The association between body mass index and health-related quality of life: influence of ethnicity on this relationship. Diabetes Obes Metab (2012) 0.85

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplant (2005) 0.84